公开(公告)号：US20070027203A1

公开(公告)日：2007-02-01

申请号：US11494362

申请日：2006-07-26

申请人： Ruihuan Chen ,  Simon Mencher ,  Allen Tsao ,  Xiao Mei Liu ,  Longgui Wang

发明人： Ruihuan Chen ,  Simon Mencher ,  Allen Tsao ,  Xiao Mei Liu ,  Longgui Wang

IPC分类号： A61K31/404

CPC分类号： A61K31/404 ,  Y02A50/411 ,  Y02A50/463 ,  A61K2300/00

摘要： The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-α or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.

摘要翻译： 本发明涉及一种治疗哺乳动物炎症性关节炎的方法。 该方法通常包括向动物施用治疗有效量的至少一种选自靛蓝，异靛蓝，靛玉红或其衍生物的化合物，例如NATURA-α或NATURA。 本发明进一步涉及药物组合物，其包含治疗有效量的至少一种本发明化合物，抗炎性关节炎药物和药学上可接受的载体。

公开(公告)号：US07855223B2

公开(公告)日：2010-12-21

申请号：US11494362

申请日：2006-07-26

申请人： Ruihuan Chen ,  Simon K. Mencher ,  Allen Tsao ,  Xiao Mei Liu ,  Longgui Wang

发明人： Ruihuan Chen ,  Simon K. Mencher ,  Allen Tsao ,  Xiao Mei Liu ,  Longgui Wang

IPC分类号： A61K31/40 ,  A61K31/405 ,  A61K31/56 ,  A61K31/19

CPC分类号： A61K31/404 ,  Y02A50/411 ,  Y02A50/463 ,  A61K2300/00

摘要： The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-α or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.

摘要翻译： 本发明涉及一种治疗哺乳动物炎症性关节炎的方法。 该方法通常包括向动物施用治疗有效量的至少一种选自靛蓝，异靛，靛玉红或其衍生物的化合物，例如NATURA-α或NATURA。 本发明进一步涉及药物组合物，其包含治疗有效量的至少一种本发明化合物，抗炎性关节炎药物和药学上可接受的载体。